Quarterly ResultMay 15, 2026, 04:43 PM
Shuttle Pharma Q1 Net Loss $2.15M; Going Concern Doubt Raised
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. reported a net loss of $2.15 million for the three months ended March 31, 2026, an improvement from a $3.05 million loss in the prior year. The company's financial statements include a going concern warning, indicating that existing cash resources are insufficient for the next twelve months. This follows the acquisition of Molecule.ai's AI-driven drug discovery platform in November 2025 and the winding down of Ropidoxuridine clinical trials. In March 2026, the company raised approximately $3.2 million in net proceeds from a public offering of common stock and pre-funded warrants.
Key Highlights
- Net loss for Q1 2026 was $2.15 million, an improvement from $3.05 million in Q1 2025.
- Net loss per share improved to $(0.43) in Q1 2026 from $(7.60) in Q1 2025.
- Company faces substantial doubt about its ability to continue as a going concern.
- Cash and cash equivalents increased to $1.09 million as of March 31, 2026.
- Working capital deficit was approximately $5.8 million as of March 31, 2026.
- Raised $3.2 million net cash from a public offering of common stock in March 2026.
- Acquired Molecule.ai AI platform and wound down Ropidoxuridine clinical trials.
- Q1 2026 R&D expenses decreased to $0.27 million from $1.57 million in Q1 2025.
Price Impact
More from SHPH